Cytomegalovirus-specific T cells (ViraCyte)

N/A

Report date: 2025/04/23 20:01:04

Base Information

Drug NameCytomegalovirus-specific T cells (ViraCyte)

Drug Alias NameViralym-CHLA-matched Viralym-C cellsCMV-specific T cells - ViraCyteCMV-specific T cell therapy - ViraCyteCytomegalovirus-specific T cell therapy - ViraCyte +[6]

ClassificationCell and gene therapy > Cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsCytomegalovirus Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesViracyte Llc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesKalaris Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsCytomegalovirus Infections

Other Information

ATC CodeN/A